Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Profit After Tax (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Profit After Tax data on record, last reported at $988000.0 in Q4 2025.

  • For Q4 2025, Profit After Tax rose 130.44% year-over-year to $988000.0; the TTM value through Dec 2025 reached -$63.4 million, down 241.55%, while the annual FY2025 figure was -$63.4 million, 241.01% down from the prior year.
  • Profit After Tax reached $988000.0 in Q4 2025 per LCTX's latest filing, up from -$29.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $988000.0 in Q4 2025 and bottomed at -$30.5 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$7.6 million, with a median of -$5.8 million recorded in 2024.
  • The widest YoY moves for Profit After Tax: up 130.44% in 2025, down 890.08% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$7.8 million in 2021, then rose by 18.78% to -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 32.02% to -$3.2 million in 2024, then soared by 130.44% to $988000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $988000.0 in Q4 2025, -$29.8 million in Q3 2025, and -$30.5 million in Q2 2025.